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j Abstract Objective To com-
pare the efficacy, safety, and
tolerability of olanzapine and
quetiapine in adolescents with first
episode psychosis. Method Fifty
adolescents (age 16 ± 1.25) with a
first episode of psychosis were
randomized to quetiapine or
olanzapine in a 6-month open
label study. Efficacy and side effect
scales, as well as vital signs and
laboratory data were recorded at
baseline, 7, 15, 30, 90, and
180 days (end of study). Results
Out of the total sample included in
the study, 32 patients completed
the trial (quetiapine n = 16, olan-
zapine n = 16). Patients in both
treatment groups had a significant
reduction in all clinical scales with
the exception of the negative scale
of the Positive and Negative
Symptom Scale (PANSS) for olan-
zapine and the general psychopa-
thology scale of the PANSS for
quetiapine. The only difference
between treatment arms on the
clinical scales was observed on the
patients’ strength and difficulties
questionnaire (SDQ) scale, with
greater improvement for olanza-
pine. Patients on olanzapine
gained 15.5 kg and patients on
quetiapine gained 5.5 kg.
Conclusion Olanzapine and
quetiapine reduced psychotic
symptoms in this adolescent sam-
ple. Patients on olanzapine gained
significantly more weight. Side
effects with both drugs seemed to
be more prevalent than those
reported in adult studies.
j Key words olanzapine –
quetiapine – safety –
tolerability – adolescent –
first episode psychosis
Introduction
There has been a drastic increase in the prescription
of antipsychotics in children and adolescents in
recent years [32]. Nevertheless, there is very limited
efficacy or safety evidence from randomized con-
trolled trials to support these prescribing trends in
children and adolescents with psychotic symptoms
[5]. In fact, there have been more studies with SGA for
the treatment of disruptive behaviors and develop-
mental disorders than in patients with psychotic
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symptoms [8]. To our knowledge, only three double-
blind studies have compared the efficacy of different
antipsychotics. Moreover, two of these studies were
performed with a very low prevalence entity:
treatment resistant patients with childhood-onset
schizophrenia [21, 37]. Kumra et al. [21] found that
clozapine was superior to haloperidol in the treatment
of 21 treatment resistant patients with prepubertal-
onset schizophrenia. In a more recent study, cloza-
pine was significantly superior to olanzapine only for
the treatment of negative symptoms [37]. In the only
other double-blind randomized study, Sikich et al.
[38] studied 50 patients with psychotic symptoms,
with a mean length of illness of 2.4 years. Haloperidol,
olanzapine, and risperidone showed similar efficacy
in symptom reduction. In this study, weight gain and
extrapyramidal effects appeared more prevalent and
severe than reported in adults. Most studies are short
term, usually lasting 6–8 weeks [37, 38]. We are not
aware of any previous randomized controlled trial
with two SGAs in first episode psychosis in adoles-
cence.
This study was designed to provide prospective,
randomized information at 6 months about the effi-
cacy and safety of two-second generation antipsy-
chotics widely prescribed in pediatric populations.
Based on previous studies in adult first episode psy-
chosis and studies on tolerability in pediatric popu-
lations, we hypothesized that there would not be a
difference between quetiapine and olanzapine in
terms of symptom reduction, and that side effects
would be very prevalent in this population and dif-
ferent for the two antipsychotics.
Methods
j Study design
This is a 6-month, comparative, randomized (que-
tiapine vs. olanzapine), open label, parallel group
study in adolescent patients with first episode psy-
chosis. In this article, we report on clinical efficacy,
tolerability, and safety of antipsychotic drug treat-
ment. However, the primary outcome for this trial was
cognitive efficacy. Results for cognitive outcome are
reported elsewhere (Robles et al., submitted). There-
fore, here we focus on the clinical secondary variables.
j Subjects
Fifty patients consecutively admitted to the Adolescent
Unit of Hospital General Universitario ‘‘Gregorio Mar-
an˜o´n’’ (Madrid, Spain) with a diagnosis of psychosis
(i.e., schizophrenia or any other psychotic disorder
according to DSM-IV criteria) were invited to participate
in the study. All patients had a first episode of psychosis
before the age of 18, lasting less than 1 year after onset of
the first positive symptom (mean duration of delusions
0.3 ± 0.3 years; hallucinations 0.4 ± 0.5 years). Ado-
lescents were 12–18 years of age.
Diagnostic information was collected at baseline by
means of the Kiddie-SADS-Present and Lifetime
Version (K-SADS-PL). A clinical psychiatrist with
formal training in the K-SADS-PL interviewed par-
ticipants and administered diagnostic, psychiatric,
safety, and tolerability scales over the six research
visits (see ‘‘Outcome measures’’ for scales and fre-
quency). The Internal Review Board (IRB) approved
all procedures, including recruitment and consent.
Written informed consent was obtained from partic-
ipants and their parents or legal guardians prior to
enrollment in the study.
We excluded subjects if the psychotic symptoms
appeared to result from acute intoxication or with-
drawal (if psychotic symptoms did not persist after
14 days of a negative urine drug screening), if they
met DSM-IV criteria for any substance abuse, mental
retardation, or pervasive developmental disorder,
suffered from any organic central nervous system
disorder, had a history of traumatic brain injury with
loss of consciousness, were pregnant or breast-feed-
ing, or were taking olanzapine or quetiapine before
enrolment. Use of other antipsychotic drugs other
than olanzapine or quetiapine before enrolment was
allowed.
Patients were diagnosed again at 6 months by the
patient’s attending psychiatrist, according to DSM-IV
criteria. The final sample included 17 patients with
schizophrenia, 13 patients with bipolar disorder, and
20 patients with ‘‘other’’ psychotic disorders. Specific
diagnoses at 6 months for patients included in the
two treatment arms are provided in Table 1. Figure 1
provides a detailed explanation of the flow of partic-
ipants throughout the trial.
j Randomization
Adolescents were randomized to one of two treatment
groups (quetiapine or olanzapine). Stratified random
sampling was conducted according to two participant
characteristics: age and gender.
j Medication
Four patients randomized to quetiapine and eight
patients randomized to olanzapine had previously
received antipsychotics (16.7% of the quetiapine
group and 30.8% of the olanzapine group). All pa-
tients were prescribed risperidone 2–6 mg (flexible
C. Arango et al. 419
Olanzapine and quetiapine in adolescence
dose at the discretion of the clinician), between 3 and
5 days prior to randomization. For patients that were
not on antipsychotic treatment before, we needed
between 3 and 5 days to have the informed consent
explained to patients and legal representatives and
have it signed. The IRB from our hospital did not
allow having patients off medication before random-
ization. 25 patients were antipsychotic naı¨ve prior to
inclusion in the study (quetiapine: n = 15; olanza-
pine: n = 10). In addition we thought that the use of
the same antipsychotic before randomization would
reduce the heterogeneity of carrying over effects
from previous different antipsychotics. Antipsychot-
ics, other than the study drugs, were not permitted
throughout the clinical trial.
Adolescents were randomized to one of two treat-
ment groups: quetiapine (n = 24) or olanzapine
(n = 26). The dose administered was determined at the
discretion of the clinician. Adjunctive medications other
than different antipsychotics were allowed during the
clinical trial.
j Outcome measures
Efficacy measures
Clinical evaluations were performed by one of the four
adolescent psychiatrists participating in the research
study. The primary outcome measure for symptom
reduction was the Positive and Negative Symptoms
Scale (PANSS) [18] Secondary clinical outcome mea-
sures were: the Global Assessment Scale for Children
(C-GAS) [35], Clinical Global Impression-Severity score
(CGI-S) [14], Hamilton Depression Rating Scale
(HDRS-21) [15], and the Young Rating Mania Scale
(YRMS) [42]. The strengths and difficulties question-
naire (SDQ) [11, 12] for children and adolescents was
also administered. This pediatric scales provide not
Table 1 Socio-demographic and clinical characteristics
Variables Quetiapine Olanzapine Analysis
n Mean SD n Mean SD Statistic dfd P
Age (years)a 24 16.3 1.1 26 15.7 1.4 U – 0.132
Parental years of educationa 21 10.6 3.5 15 9.4 3.8 U – 0.736
n %e n %e Statistic df P
Genderb v2 1 0.848
Male 19 79.2 20 76
Female 5 20.8 6 24
Race or ethnic groupc v2 3 0.030
Caucasian 21 87.5 20 76.9
Caribbean Black 2 8.3 0 0
Hispanic 0 0.0 6 23.1
Gipsy 1 4.2 0 0
Parental socioeconomic status (Hollingshead Redlich)b 8 100.0 9 100 v2 2 0.667
I 0 0.0 0 0
II 0 0.0 0 0
III 2 25.0 4 44.4
IV 3 37.5 2 22.2
V 3 37.5 3 33.3
n %e n %e Statistic df P
DSM-IV diagnosisb v2 2 0.425
Schizophrenia 8 33.3 9 34.6
Bipolar disorder 8 33.3 5 19.2
Other psychoses 8 33.3 12 46.2
Psychosis NOS 2 25 4 33.3
Schizoaffective disorder 2 25 3 25
Schizophreniform disorder 2 25 2 16.6
Major depressive episode with psychotic features 2 25 3 25
NOS not otherwise specified
aNo significant differences were observed between the two treatment groups (Mann–Whitney U; P > 0.05)
bNo significant differences were observed between the two treatment groups (Chi-square; P > 0.05)
cSignificant differences were observed between the two treatment groups (Chi-square; P < 0.05)
dNot applicable when using the Mann–Whitney U test
ePercentage calculated according to the total randomized sample (quetiapine n = 24, olanzapine n = 26)
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only third party and self-rated information (it has a
parent, teacher and self-rated versions), but also pro-
vide important information in addition to psychopa-
thology (behavioral, emotional, and social). All scales
were administered at baseline, visit 1 (day 7), visit 2
(day 15), visit 3 (day 30), visit 4 (day 90), and visit 5 (day
180), except for the SDQ scale (in its three versions),
which was administered only at baseline and end of
study. All scales were administered by four board-cer-
tified psychiatrists with clinical experience with chil-
dren and adolescents. Intraclass correlation coefficients
for the four psychiatrists ranged from 0.72 to 0.96 for
the total and PANSS positive, negative, and general
psychopathology subscores.
Measures of safety and tolerability
Primary outcome measures for safety and tolerability
were: weight changes (measured as increase in kilo-
grams and body mass index (BMI)), UKU scale of
adverse reactions [25], Barnes Akathisia Scale [2], and
Simpson Neurological Rating Scale for extrapyrami-
dal side effects [39]. All safety and tolerability
scales were administered visit-wise. Blood cell counts,
electrolytes, renal function, liver function, energy
metabolism (glucose, HgbA1c, lipid profile), prolac-
tin, and EKG were performed at baseline and at each
visit. All blood tests were performed in a fasting state.
j Data analysis/statistical methods
Descriptive statistics were obtained on demographic
and outcome variables, using means with standard
deviations for continuous variables and frequency
distributions for categorical variables. Differences in
qualitatively measures between groups were com-
pared by means of Chi-square. Efficacy, safety, and
tolerability measures were assessed using the Mann–
Whitney U nonparametric test to compare quetiapine
versus olanzapine at baseline and 6 months, and the
Wilcoxon nonparametric test to examine changes
between baseline and 6 months within treatment
arms. An intent-to-treat efficacy analysis was per-
formed for all patients who fulfilled the inclusion
criteria, with the last observation carried forward
(LOCF) for any patient not completing the study.
Cases in which no data was obtained after baseline
were eliminated. All statistical tests were two tailed;
alpha (level of significance) was 5%.
The SPSS 12.0.1 statistical package was used for all
analyses.
Results
j Subjects
Demographic variables for subjects participating in the
study are presented in Table 1. The treatment groups
were comparable in age, gender, time elapsed since onset
of the first psychotic symptom, parental education, and
family socioeconomic status. There was a higher pro-
portion of Hispanic patients in the olanzapine group
(Chi-square; P < 0.05). With respect to baseline symp-
tomatology, adolescents in the olanzapine group
scored worse on the general psychopathology scale
(U = 179.00, P = 0.027) and total score (U = 162.00,
Assessed for
Eligibility
Not Randomized (n=3)
-Refused to participate in the study (n=3)
Randomized
(n=50)
Assigned to Quetiapine
(n=24)
Completed
Quetiapine Trial
(n=16)
Completed
Olanzapine Trial
(n=16)
Total Withdrawn (n=8)
-Loss to Follow-up (n=3)
-Poor compliance[?] (n=1)
-Symptom Remission (n=0)
-Poor Response (PR) (n=4)
-Change to Treatment (n=0)
-Adverse Events (AE) (n=0)
Total Withdrawn (n=9)
-Loss to Follow-up (n=4)
-Poor compliance[?] (n=0)
-Symptom Remission (n=1)
-Poor Response (PR) (n=2)
-Change to Treatment (n=2)
-Adverse Events (AE) (n=0)
Assigned to Olanzapine
(n=26)
Fig. 1 Subject flowchart
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P = 0.010) of the PANSS. No differences were observed
for the positive (U = 245.00, P = 0.192) or negative
(U = 214.00, P = 0.057) scales. All patients were single
and lived with parents or guardians.
j Medication
Mean doses at 6 months were 532.8 ± 459.6 mg/day of
quetiapine and 9.7 ± 6.5 mg/day of olanzapine. Mean
doses administered for each of the two drugs at the dif-
ferent assessment points can be seen in Table 2. There
were no differences in mean treatment time between
groups, with 143.75 ± 68 days for quetiapine and 144.1 ±
62.5 for the olanzapine group. Concomitant medications
during the study are provided in Table 3. There was no
difference between groups with regard to the use of any
adjunctive medication at baseline or end of study.
j Symptom reduction
Change from baseline within treatment groups
Decreases in PANSS total score and PANSS subscales
were observed in the two treatment groups. Statisti-
cally significant decreases between baseline and
6 month assessments were observed in the PANSS
total score (W = )2.201, P = 0.028, and W = )2. 197,
P = 0.028 for olanzapine and quetiapine groups,
respectively), with the end point total score equal to
32.3% of the baseline score in the olanzapine group
and 26% of the baseline score in the quetiapine group.
The PANSS positive subscale score was significantly
decreased in the two treatment groups (W = )2.366,
P = 0.018; and W = )2.028, P = 0.043, for olanzapine
and quetiapine groups, respectively). On percentages,
these reductions were 46.4% for olanzapine, and
35.2% for quetiapine group. On the PANSS negative
subscale, significant decreases were observed only for
the quetiapine group (olanzapine: W = )2.533,
P = 0.833; quetiapine W = )2.533, P = 0.011). Per-
centages of reduction were: 16.5% in the olanzapine
group, and 25.6% in the quetiapine group. On the
other hand, a significant decrease was observed on the
PANSS general psychopathology subscale in the
olanzapine group (W = )2.201, P = 0.028), but not
the quetiapine group (W = )2.201, P = 0.063). On
percentages, PANSS general psychopathology sub-
scale scores, diminished a 33.2% in the olanzapine
group, and a 25% in the quetiapine group.
See Figs. 2 and 3 and changes in PANSS positive
and PANSS negative scores during the trial.
The HDRS-21, YMRS, and CGI-S scores were all
significantly decreased in both treatment groups. The
C-GAS scores also significantly improved in the two
treatment groups (Table 4).
The SDQ patient subscore was significantly de-
creased in patients treated with olanzapine
(W = )2.675, P = 0.007), but not in those treated
with quetiapine (W = )0.534, P = 0.593). The other
SDQ subscales (parent and teacher subscores) were
significantly decreased in both treatment groups
(Table 4).
Comparison of treatment groups
Between-group comparisons of improvement on all
the symptomatic scales failed to detect statistical
differences (Table 4) with the exception of the SDQ
subscale for patients (U = 122.500, P = 0.026) in fa-
vor of olanzapine.
j Safety measures
Spontaneous adverse events (i.e. other side effects
than assessed by means of UKU) were reported for
nine patients in the study: six patients on quetiapine
and three patients on olanzapine. Only one of the
reported adverse events was considered serious:
physical aggression towards others, committed by a
Table 2 Quetiapine and olanzapine doses (mg/day) administered visit-wise
Visit Quetiapine Olanzapine
Mean SD Mean SD
Visit 0 (baseline) 116.67 95.46 7.60 2.50
Visit 1 (day 7) 406.25 259.73 13.37 5.74
Visit 2 (day 15) 552.50 395.05 14.81 6.71
Visit 3 (day 30) 618.48 423.45 15.96 8.10
Visit 4 (day 90) 406.25 200.78 11.25 7.57
Visit 5 (day 180) 532.81 459.59 9.71 6.55
Table 3 Adjunctive pharmacological treatments during participation in the
study
Quetiapine Olanzapine
n %b n %b
Total patients with adjunctive treatmenta 21 87.5 21 80.8
Anticholinergics 3 12.5 8 30.8
Beta-blockers 2 8.3 1 3.8
Benzodiazepines 14 58.3 17 65.4
Antidepressants 8 33.3 10 38.5
Antiepileptics 7 29.2 7 26.9
Lithium 6 25.0 2 7.7
Analgesics 2 8.3 0 0.0
Iron compounds 1 4.2 0 0.0
Non-steroidal anti-inflammatory drugs 1 4.2 0 0.0
Cough medications 1 4.2 0 0.0
aThere were no significant differences between the two treatment groups (Chi-
square; P > 0.05)
bPercentage calculated according to the total sample (quetiapine n = 24,
olanzapine n = 26)
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patient on quetiapine. The adverse event was con-
sidered unrelated to medication. Three patients
experienced adverse events considered of moderate
intensity: polyarthritis (patient on quetiapine), wrist
fracture (patient on olanzapine), and muscle con-
tracture (patient on quetiapine). All other adverse
events were mild in intensity. None of the drop-outs
from the study were due to an adverse event.
Change from baseline within treatment groups
Table 5 shows data on subjective side effect symp-
toms, as measured with the UKU, that were present at
least in a 20% of patients at any time during the study
with either of the two drugs.
Significant weight gain was observed in both
groups (olanzapine: 15.5 kg, W = )3.621, P < 0.001;
quetiapine: 5.4 kg, W = )2.899, P = 0.004). Weight
gain was disproportionate to increase in height, with
BMI increases also significant for both groups (olan-
zapine baseline 21.7, end of study 27.1, W = )3.181,
P = 0.001; quetiapine baseline 21.5, end of study 23.3,
W = )2.919, P = 0.004).
The effect of each treatment on various safety
parameters is summarized in Table 5.
There were no significant within-group changes
with either of the two antipsychotics in systolic or
diastolic blood pressure, heart rate, or QTc. There
were no differences in electrolytes, liver function, re-
nal function, energy metabolism (glucose, HgbA1c,
lipid profile), or hemogram (hematite, hematocrit)
parameters in either of the two groups. With respect
to cholesterol levels, an increase was observed in HDL
for the quetiapine group (W = )2.670, P = 0.008),
and an increase in total cholesterol for both quetia-
pine (W = )2.638, P = 0.008) and olanzapine
(W = )2.379, P = 0.017). A decrease in the thyroid
hormone T4 was observed for the quetiapine group
28
26
24
22
20
18
16
14
12
10
Baseline Day 7 Day 15 Day 30 Day 90 Day 180
Quetiapine
Olanzapine
Fig. 3 PANSS positive subscale
scores over time by treatment group
29
27
25
23
21
19
17
15
Baseline Day 7 Day 15 Day 30 Day 90 Day 180
Quetiapine
Olanzapine
Fig. 2 PANSS negative subscale
scores over time by treatment group
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(W = )2.226, P = 0.026), but not for the olanzapine
group (W = )1.485, P = 0.138).
Comparison of treatment groups
There were no significant between-group differences
in the changes in prevalence of UKU items with the
exception of rigidity (Mann–Whitney, P < 0.05).
Rigidity was more frequently present in patients
treated with olanzapine.
Patients on olanzapine gained more weight
(U = 34.500, P < 0.001) and had a greater increase in
BMI (U = 49.000, P = 0.015) than patients treated
with quetiapine (Table 5; Fig. 4).
There were no between-group differences in any of
the cardiac, liver function, renal function, energy
metabolism (glucose, HgbA1c, lipid profile), hemo-
gram, or thyroid parameters. The HDL increase was
more prominent in patients on quetiapine than in
patients on olanzapine (U = 31.000, P = 0.019).
Discussion
Adolescent patients treated with both olanzapine and
quetiapine had a reduction in symptomatology over a
6-month period. The drugs had different side effect
profiles. No significant differences were observed be-
tween the two treatment arms at the 6-month evalu-
ation in terms of clinical reduction in symptoms, with
patients in both arms experiencing significant clinical
improvements, with the exception in one of the SDQ
scores. Patients receiving olanzapine rated themselves
as having improved more in terms of behaviour than
patients receiving quetiapine. This difference was not
supported by the parent and teacher versions of the
scale, which showed significant improvements with
either of the two antipsychotics. This result is in line
with some previous studies reporting a better sub-
jective feeling with olanzapine than with other second
generation antipsychotics such as clozapine or ris-
peridone [24, 31], although results are controversial
(see, among others, [19, 40, 41]), and this result could
also well manifest a Type I error. To our knowledge,
no formal comparative studies have been carried out
on subjective feelings of adolescents taking antipsy-
chotics, and this is an area that definitely needs more
research, as subjective feelings have been related to
medication compliance, quality of life, and functional
outcome [6, 30, 31].
Both groups showed significant reduction in both
total psychopathology and positive symptoms. How-
ever, a reduction in negative symptoms was observed
only for patients on quetiapine, whereas a reduction
in general psychopathology was significant only forTa
b
le
4
Sa
fe
ty
an
d
to
le
ra
bi
lit
y
m
ea
su
re
s:
ba
se
lin
e
an
d
6
m
on
th
s
Q
ue
tia
pi
ne
O
la
nz
ap
in
e
An
al
ys
is
Ba
se
lin
e
6
m
on
th
s
Ba
se
lin
e
6
m
on
th
s
Q
ue
tia
pi
ne
(B
as
el
in
e
vs
.
6
m
on
th
s)
O
la
nz
ap
in
e
(B
as
el
in
e
vs
.
6
m
on
th
s)
Ev
ol
ut
io
n
of
Q
ue
tia
pi
ne
vs
.
O
la
nz
ap
in
e
n
M
ea
n
±
SD
n
M
ea
n
±
SD
n
M
ea
n
±
SD
n
M
ea
n
±
SD
Si
g
Si
g
Si
g
CG
I
23
5.
04
±
1.
30
24
2.
96
±
1.
40
26
5.
46
±
0.
86
26
3.
54
±
1.
30
W
=
)
3.
86
2,
P
<
0.
01
W
=
)
4.
33
6,
P
<
0,
01
U
=
27
4.
00
0,
P
=
0.
60
5
YO
U
N
G
23
15
.7
0
±
12
.8
5
24
5.
50
±
6.
39
26
18
.7
3
±
12
.6
9
26
6.
34
±
9.
62
W
=
)
3.
24
2,
P
=
0,
00
1
W
=
)
3.
76
9,
P
<
0,
01
U
=
26
2.
50
0,
P
=
0.
46
4
H
AM
IL
TO
N
22
17
.2
7
±
9.
69
24
8.
00
±
6.
70
24
17
.8
3
±
10
.0
3
26
9.
12
±
7.
91
W
=
)
3.
53
0,
P
<
0,
01
W
=
)
2.
60
2,
P
=
0,
00
9
U
=
24
4.
00
0,
P
=
0.
66
0
G
AF
24
41
.1
7
±
15
.5
6
24
67
.7
9
±
16
.7
9
26
37
.5
8
±
17
.3
3
26
61
.8
8
±
16
.0
1
W
=
)
4.
20
4,
P
<
0,
01
W
=
)
4.
05
5,
P
<
0,
01
U
=
30
9.
00
0,
P
=
0.
11
8
PA
N
SS
Po
si
tiv
e
24
23
.2
5
±
7.
25
24
15
.0
8
±
4.
07
26
26
.1
2
±
4.
10
26
14
.0
4
±
4.
75
W
=
)
2.
02
8,
P
=
0.
04
3
W
=
)
2.
36
6,
P
=
0.
01
8
U
=
23
1.
50
0,
P
=
0.
11
8
PA
N
SS
N
eg
at
iv
e
24
21
.8
8
±
6.
83
5
24
16
.2
9
±
5.
15
26
26
.5
8
±
8.
34
26
22
.1
5
±
7.
24
W
=
)
2.
53
3,
P
=
0.
01
1
W
=
)
0.
21
0,
P
=
0.
83
3
U
=
26
3.
00
0,
P
=
0.
34
0
PA
N
SS
G
en
er
al
22
46
.0
5
±
11
.2
6
24
34
.4
5
±
9.
89
26
52
.9
6
±
10
.8
4
26
35
.4
2
±
8.
88
W
=
)
1.
85
9,
P
=
0.
06
3
W
=
)
2.
20
1,
P
=
0.
02
8
U
=
20
5.
00
0,
P
=
0.
09
3
PA
N
SS
To
ta
l
22
91
.0
5
±
21
.4
2
24
67
.2
9
±
17
.8
6
26
10
5.
65
±
19
.9
7
26
71
.6
2
±
17
.3
3
W
=
)
2.
19
7,
P
=
0.
02
8
W
=
)
2.
20
1,
P
=
0.
02
8
U
=
18
7.
50
0,
P
=
0.
41
SD
Q
Pa
tie
nt
19
24
.1
6
±
5.
08
22
24
.3
6
±
6.
15
21
23
.5
2
±
5.
1
22
20
.8
2
±
5.
96
W
=
)
0.
53
4,
P
=
0.
59
3
W
=
)
2.
67
5,
P
=
0.
00
7
U
=
12
2.
50
0,
P
=
0.
02
6
SD
Q
Pa
re
nt
16
22
.1
3
±
7.
67
19
21
.6
3
±
7.
51
20
23
.7
0
±
5.
29
21
22
.8
1
±
6.
35
W
=
)
0.
94
3,
P
=
0.
34
5
W
=
)
0.
86
4,
P
=
0.
38
8
U
=
15
6.
50
0,
P
=
0.
90
5
SD
Q
Te
ac
he
r
7
22
.1
4
±
4.
60
10
21
.3
±
5.
46
12
21
.5
0
±
5.
25
17
21
.7
1
±
4.
77
W
=
)
1.
00
0,
P
=
0.
31
7
W
=
0,
P
=
1
U
=
36
.0
00
,
P
=
0.
19
0
424 European Child & Adolescent Psychiatry (2009) Vol. 18, No. 7
 Steinkopff Verlag 2009
those patients on olanzapine. Given the lack of dif-
ferences in the different symptom domains between
different antipsychotics in previous studies with
much larger samples (CATIE [23], EUFEST [17],
CUtLASS [16]), these findings may be more likely
constitute a Type II error due to small sample size
than a true difference reflecting a different pharma-
cological profile for the two drugs.
Results are comparable to previous reports show-
ing efficacy of SGAs in pediatric populations with
psychotic symptoms. In a previous 8-week double-
blind, randomized, controlled trial in 50 children and
adolescents with psychotic symptoms, comparing
risperidone, olanzapine, and haloperidol, there was
no difference in efficacy among the drugs, with all
three antipsychotics providing a significant reduction
in psychotic symptoms [38]. More recently, a 12-week
open-label, randomized study comparing risperidone
and olanzapine efficacy in 25 child-onset schizo-
phrenia patients reported that both drugs provided a
similar significant reduction in psychotic symptoms
[28]. In an 8-week open label study in 16 adolescent
patients with schizophrenia, schizophreniform, or
schizoaffective disorders, olanzapine significantly
decreased PANSS scores [9]. Further studies are
needed to elucidate whether different antipsychotics
have distinct efficacy profiles for different symptom
domains, and more especially, different safety and
side effect profile.
It is noteworthy that a high prevalence of side ef-
fects was found in this adolescent sample. Despite the
lack of significant differences between the two treat-
ments with respect to the presence of side effects as
measured by the UKU (with the exception of rigidity
and diminished sexual desire), there were many other
symptoms present in more than 20% of patients
Table 5 Side effects as measured with the UKU
Subjective side effect Quetiapine
(n = 24)
Olanzapine
(n = 26)
n (%) n (%)
Ever End point Ever End point
Concentration difficulties 16 (67) 6 (37) 18 (72) 9 (56)
Asthenia/lassitude/increased
fatigability
19 (79) 9 (56) 19 (73) 9 (53)
Sleepiness/sedation 19 (79) 11 (69) 21 (84) 12 (71)
Failing memory 14 (58) 4 (25) 12 (52) 7 (41)
Depression 9 (37) 8 (50) 11 (44) 8 (47)
Tension/inner unrest 15 (62) 7 (44) 13 (54) 5 (29)
Increased duration of sleep 11 (46) 6 (37) 12 (48) 6 (35)
Reduced duration of sleep 4 (17) 0 (0) 6 (25) 1 (6)
Increased dream activity 9 (39) 4 (25) 6 (26) 2 (12)
Emotional indifference 7 (29) 3 (19) 14 (56) 6 (35)
Rigiditya,b 4 (17) 0 (0) 7 (29) 0 (0)
Hypokinesia/akinesia 11 (46) 2 (12) 14 (54) 4 (23)
Tremor 7 (37) 4 (25) 13 (50) 4 (23)
Akathisia 6 (26) 0 (0) 8 (32) 3 (18)
Accommodation disturbances 6 (26) 2 (12) 7 (32) 5 (29)
Increased salivationb 10 (42) 2 (12) 13 (52) 2 (12)
Reduced salivation 9 (39) 4 (25) 2 (8) 1 (6)
Constipation 10 (42) 1 (6) 7 (27) 1 (6)
Polyuria/polydipsia 7 (30) 4 (25) 8 (31) 5 (29)
Orthostatic dizziness 3 (13) 2 (12) 5 (21) 1 (6)
Palpitations/tachycardia 11 (46) 1 (12) 8 (35) 1 (6)
Increased tendency to sweat 8 (33) 1 (6) 7 (28) 5 (29)
Weight gain 13 (72) 8 (50) 20 (91) 15 (88)
Amenorrhea 1 (20) 0 (0) 4 (50) 0 (0)
Increased sexual desire 1 (6) 0 (0) 5 (28) 2 (14)
Dry vagina 0 (0) 0 (0) 2 (22) 0 (0)
Tension headache 6 (25) 3 (19) 6 (24) 5 (29)
Only those with at least 20% prevalence at some point during the study are
shown in the table
aMann–Whitney U test for independent samples; significant differences when
P < 0.05
bWilcoxon test for non-independent samples; significant differences when
P < 0.05
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Fig. 4 Change in weight over time
by treatment group
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throughout the study. More than 70% of patients in
both groups experienced somnolence at some point
during the study and, more importantly, 69% of pa-
tients on quetiapine and 71% of patients on olanza-
pine experienced somnolence after 6 months of
treatment. In addition, 37% of patients on quetiapine
and 56% of patients on olanzapine experienced lack of
concentration. These are symptoms with important
daily living implications in school-age patients that
should be taken in consideration when prescribing
antipsychotics [1]. Clearly, more data on safety and
tolerability of antipsychotics is needed in this popu-
lation.
Most of the patients in this study experienced
substantial weight gain. These data are clinically
important for many reasons. A weight gain greater
than 15 kg in 6 months changes the body’s physical
appearance at an age of great emotional turmoil. This
may be specifically important in terms of treatment
adherence in adolescents who worry with their
physical appearance [1]. We did not find any differ-
ences between the two drugs in terms of drug dis-
continuation, but this could be due to the short
follow-up or the clinical trial setting. Also noteworthy
is the increased risk of chronic health problems
associated with obesity such as diabetes, hyperten-
sion, and cardiovascular morbidity. These increases
in weight are similar to those reported in first episode
studies in adults on quetiapine [10, 20]. For olanza-
pine, we have been able to locate only studies
assessing adult first episode patients for 12 weeks
with 6–7.3 kg weight gain [24, 34], and up to
4 months with 7.7 kg weight gain [34]. Weight gain
and metabolic changes have been described in this
population [4, 5]. However, the weight gain in the
present study is greater than that seen in more
chronic pediatric patients [9, 29, 37, 38] that may have
already gained weight due to antipsychotic treatment
prior to study entry. Therefore, first episode psychosis
patients may be a population at greater risk for this
side effect, regardless of the age. This study also
points to the need to assess weight gain in studies
with longer follow-up periods, as this side effect does
not seem to plateau after the first 6 months of treat-
ment. Weight should be routinely measured quanti-
tatively, since scales such as the UKU that measures
only if weight gain is present or absent, miss signifi-
cant differences between drugs that are clinically
meaningful, as was the case in this study (Table 5).
Our results relative to free-thyroid hormone (FT4)
reduction are in the line with previous reports in adult
[3] and adolescent populations [10, 26, 27, 36] using
similar antipsychotic doses and treatment times.
Treatment with quetiapine was related to a significant
decrease in FT4. Kelly and Conley argue that this effect
may be secondary to competitive metabolism of thy-
roid hormones and quetiapine by UDP-glucurono-
syltransferase [27]. In our study, FT4 levels were
within normal limits both at baseline and the 6-month
assessment. Therefore, such a decrease did not have
clinical implications. Further studies are needed to
evaluate FT4 changes with long-term treatment.
We also found that total cholesterol levels in-
creased significantly in patients receiving olanzapine
and quetiapine. HDL cholesterol increased only in the
group treated with quetiapine. Thus, the increase in
total cholesterol in patients treated with olanzapine
seems to be driven by a non-significant increase in
LDL cholesterol. Olanzapine was reported to be re-
lated to an increase in total cholesterol in a study in
five adolescents [13], although findings on the effects
of olanzapine, risperidone, and quetiapine on cho-
lesterol levels among adolescents are not conclusive
[7, 10, 20, 38].
Regarding concomitant medications, patients on
olanzapine experienced dystonia and required anti-
cholinergics in a higher proportion than patients on
quetiapine, although this difference was not signifi-
cant. This may indicate a higher susceptibility to
extrapyramidal symptoms with olanzapine as com-
pared to quetiapine in this population. In a previous
study on SGA tolerability in a pediatric population,
we reported that patients treated mostly with SGAs
over a one-year showed more dyskinetic movements
than patients treated for less than 1 month [22].
Maturation of the dopamine system during childhood
and adolescence may affect susceptibility to motor
side effects differently, depending on age. Therefore,
subgroups should be stratified by age when assessing
dopamine-related side effects in young people ex-
posed to SGAs.
There are several methodological limitations to
this study. Firstly, we used an open-label instead of a
double-blind design, which can change the expecta-
tions of patients and their caregivers, as well as
therapists, even when medication is assigned ran-
domly, thus influencing the outcome of treatment.
Secondly, the small sample size of our groups may
limit the study’s ability to detect moderate to small
differences between treatments that may be clinically
significant (Type II error). In addition, it makes it
difficult to do any sort of subgroup analyses, for in-
stance between different diagnoses or age subgroups.
Thirdly, a variety of concomitant medications was
used. Although there were no significant differences
between any particular class of adjunctive medication
used in the two groups, it is theoretically possible that
both the efficacy and side effects observed in this
study were due to or modulated by the adjunctive
medication rather than the antipsychotic drug.
Fourthly, although similar completion rates were ob-
served for both the quetiapine sample (66.7%) and the
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olanzapine sample (61.5%), we observed high drop-
out rates in both treatment arms, which may limit the
generalizability of our results. However, the literature
reveals 6-month studies with higher attrition rates. In
a study comparing quetiapine 300, 600 mg, and hal-
operidol, drop-out rates increased to 58, 50, and 35%,
respectively, before week 24 [40]. Furthermore, in
another 6-month study, only 44% of the entire sample
(total n = 12) completed the entire protocol [33]. Fi-
nally, we used a heterogeneous sample of diagnoses.
Differential diagnosis of psychotic disorders is very
difficult in a pediatric population due to the atypi-
cality and non-specificity of symptoms in psychotic
episodes at this age (e.g., noncongruent delusions or
hallucinations in a first episode bipolar patient) and
the lack of longitudinal information about the disease
course. In addition, antipsychotics have no proven
disease specific efficacy or safety profile and are
commonly used in all the diagnoses included in this
sample. The heterogeneity of this sample should be
taken into account when assessing the generalizability
of the study. Diagnostic differences may also influ-
ence the use of or the response to concomitant
medications.
In summary, patients in both treatment groups had
a significant reduction in most clinical measurements.
Side effects were common with the two drugs. The
increase in weight experienced by patients treated
with olanzapine during the 6 months of the study
does not seem to be counterbalanced by better effi-
cacy and, therefore, olanzapine should not be a first
choice drug for this population.
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